Conversations in Drug Development
Science:Life Sciences
In this episode of Conversations in Drug Development, our host Harriet Edwards, is joined by Director of Regulatory Affairs, Dr Sabine Ruehle, to discuss the challenges of navigating genetically modified organism (GMO) regulations in clinical trials within Europe. This discussion helps decipher the nuanced environment of GMOs and their associated risks unique within the European framework. Join us as we explore the outdated definition of GMOs, the complexities of their classification, and the impact of genome editing technologies.
More Episodes
Navigating the FDA Landscape: More Changes, and What's Next?
2025-10-23
345
2025-10-23
345
How to Effectively De-Risk your IND Process
2025-02-11
724
2025-02-11
724
Navigating the Future of EU Health Technology Assessments
2024-10-16
359
2024-10-16
359
A Guide to Marketing Authorization Applications in Europe
2024-09-24
391
2024-09-24
391
Navigating the new EU Clinical Trials Regulation
2024-08-13
503
2024-08-13
503
Demystifying Regulatory Designations in Drug Development
2024-07-10
386
2024-07-10
386
Exploring Genome Editing Technologies in Drug Development
2024-06-19
347
2024-06-19
347
The Most Essential Tips for Biotechs Seeking Investment
2024-06-03
369
2024-06-03
369
The Use of ATMPs in Oncology Clinical Trials
2024-05-21
321
2024-05-21
321
The Regulatory Challenges of Rare Disease Drug Development
2024-02-28
497
2024-02-28
497
Get this podcast on your
phone, FREE
